D S Alberts
Overview
Explore the profile of D S Alberts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
367
Citations
4945
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raja F, Counsell N, Colombo N, Pfisterer J, Bois A, Parmar M, et al.
Ann Oncol
. 2013 Nov;
24(12):3028-34.
PMID: 24190964
Background: The majority of women with ovarian cancer develop recurrent disease. For patients with a platinum-free interval of >6 months, platinum-based chemotherapy is a treatment of choice. The benefit of...
2.
Stratton S, Stratton M, Alberts D
Curr Oncol
. 2012 Jul;
13(5):185-6.
PMID: 22792015
No abstract available.
3.
Jeter J, Han J, Martinez M, Alberts D, Qureshi A, Feskanich D
Cancer Causes Control
. 2012 Jul;
23(9):1451-61.
PMID: 22763500
Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with lower risk of certain cancers, but data on the effect on skin cancer risk have been limited and contradictory. We prospectively...
4.
Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L, Bartels H, Bartels P, et al.
Int J Immunopathol Pharmacol
. 2011 Jun;
24(2):489-97.
PMID: 21658323
Papillary urothelial neoplasia of low malignant potential (PUNLMP) recurs in approximately 35% of patients. Conventional histopathological assessment does not distinguish non-recurrent from recurrent PUNLMP. The aim of this study is...
5.
Hess L, Barakat R, Tian C, Ozols R, Alberts D
Gynecol Oncol
. 2007 Aug;
107(2):260-5.
PMID: 17675142
Objective: Platinum/Paclitaxel-based chemotherapy is a current treatment for advanced epithelial ovarian cancer. We sought to explore the association between weight change during treatment and survival, as well as the association...
6.
Hess L, Benham-Hutchins M, Herzog T, Hsu C, Malone D, Skrepnek G, et al.
Int J Gynecol Cancer
. 2007 May;
17(3):561-70.
PMID: 17504373
Ovarian cancer is the fourth leading cause of cancer death among women in the United States. First-line chemotherapy offered to patients with ovarian cancer generally consists of an intravenous (IV)...
7.
Alberts D, Liu P, Wilczynski S, Jang A, Moon J, Ward J, et al.
Int J Gynecol Cancer
. 2007 Mar;
17(4):784-8.
PMID: 17343607
Platinum-resistant ovarian cancer continues to be a difficult therapeutic problem. Clearly, molecularly targeted agents should be evaluated in this patient population. Patients were eligible for this phase II study with...
8.
Alberts D, Markman M, Muggia F, Ozols R, Eldermire E, Bookman M, et al.
Gynecol Oncol
. 2006 Oct;
103(3):783-92.
PMID: 17070570
Ovarian cancer is the leading cause of gynecologic cancer deaths in the U.S. The concept of intraperitoneal drug delivery for therapy of intraperitoneal cancers, such as ovarian cancer, arose in...
9.
Smith H, Jiang C, Weiss G, Hallum 3rd A, Liu P, Robinson 3rd W, et al.
Int J Gynecol Cancer
. 2006 Feb;
16(1):298-305.
PMID: 16445649
The objective of this study was to determine objective response and overall survival (OS) and progression-free survival (PFS) following cisplatin plus tirapazamine treatment in eligible consenting patients with metastatic or...
10.
Ranger-Moore J, Alberts D, Montironi R, Garcia F, Davis J, Frank D, et al.
Eur J Cancer
. 2005 Aug;
41(13):1875-88.
PMID: 16087328
The ideal chemopreventive agent targets pre-neoplastic changes and intraepithelial neoplasia, preventing progression over time without notable side effects. Assessment of success of chemopreventive intervention in the short and medium term...